Trailing-twelve-month (TTM) revenue is $60.66 Million with a year-over-year growth of +6.65%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q2 FY2026Period ended 2025-10-31 | $15,035,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-15 |
| Q3 FY2026Period ended 2026-01-31 | $16,559,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-12 |
| Q4 FY2026Period ended 2026-04-30 | $13,836,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-27 |
| Q1 FY2027Period ended 2026-07-31 | $15,232,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-09-11 |
| TTM revenue | $60,662,000 |
Current P/S: $68,842,634 market capitalization ÷ $60,662,000 TTM revenue = 1.13x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T15:45:05.000Z. Latest revenue period ended 2026-07-31.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q1 FY2027 (2026-07-31): $15.23M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:46:21.361Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-04-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-04-30 · USD | FY20222022-04-30 · USD | FY20232023-04-30 · USD | FY20242024-04-30 · USD | FY20252025-04-30 · USD | FY20262026-04-30 · USD |
|---|---|---|---|---|---|---|
| License and Maintenance | N/A | N/A | N/A | N/A | $5M | N/A |
| Other Services | $1M | $2M |
$60.66M
$60.66 Million
+6.65%
vs. $56.88M a year ago (TTM)
+7.25%
5 Year compound annual growth rate
1 Year
+6.65%
3 Year
+4.81%
5 Year
+7.25%
10 Year
+17.56%
15 Year
+15.58%
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $59.42M | +$2.48M | +4.36% |
| 2025 | $56.94M | +$6.79M | +13.54% |
| 2024 | $50.16M | ($3.71M) | (6.90%) |
| 2023 | $53.87M | +$4.76M | +9.69% |
| 2022 | $49.11M | +$8.07M | +19.66% |
| 2021 |
TTM Growth
+6.65%
3-Year CAGR
+4.81%
5-Year CAGR
+7.25%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T15:46:21.361Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| N/A |
| N/A |
| N/A |
| Personalized Oncology Services | $166,000 | $49,000 | $116,000 | $18,000 | N/A | N/A |
|---|
| Pharmacology Services | $39M | $47M | $51M | $47M | $49M | $57M |
|---|
| Product and Service, Other | N/A | N/A | N/A | $3M | $4M | $2M |
|---|
| $41.04M |
| +$8.92M |
| +27.76% |
| 2020 | $32.12M | +$5.06M | +18.68% |
| 2019 | $27.07M | +$6.83M | +33.72% |
| 2018 | $20.24M | +$4.83M | +31.34% |
| 2017 | $15.41M | +$4.23M | +37.82% |
